Kairos Pharma Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer

Kairos Pharma Ltd. (NYSE American: KAPA) has announced a strategic collaboration with Bayer to evaluate its lead antibody candidate, ENV-105 (carotuximab), in combination with Bayer’s XOFIGO (radium-223 dichloride) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) involving bone. This partnership aims to address a significant unmet medical need in advanced prostate cancer, where treatment resistance often limits therapeutic options.

ENV-105 is a first-in-class CD105/BMP signaling inhibitor designed to overcome cancer drug resistance. It is currently being evaluated in Phase 1 and Phase 2 clinical trials. The company previously reported interim Phase 2 data showing median progression-free survival of more than 13 months in prostate cancer patients. XOFIGO is the only FDA-approved alpha-emitting radiopharmaceutical for symptomatic bone metastases in this patient population.

The collaboration will investigate whether ENV-105 can enhance and extend responses to XOFIGO by targeting CD105, a protein associated with treatment resistance following androgen receptor inhibition and radiation therapy. Preclinical studies have demonstrated ENV-105’s ability to re-sensitize tumors to radiation, and management believes combining the therapy with XOFIGO could provide a more durable treatment option for patients with advanced prostate cancer.

Kairos Pharma, based in Los Angeles, California, focuses on oncology therapeutics using structural biology to overcome drug resistance and immune suppression. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. As of the press release date, ENV-105 has not been approved as safe or effective by the FDA or any comparable foreign regulator.

This collaboration could have significant implications for patients with advanced prostate cancer, potentially offering a new treatment avenue that addresses resistance mechanisms. For the industry, it highlights the growing interest in combination therapies that target resistance pathways. The outcomes of this evaluation may influence future treatment protocols and provide a competitive edge for both companies in the oncology space.

For more information, visit the company’s newsroom at https://ibn.fm/KAPA and view the full press release at https://ibn.fm/emSc4.